EBV-associated gastric carcinoma occurring one year after metabolic bariatric surgery: case report and literature review
By
YingXin Wu
Xinxi Yang
Yuanyuan Chen
Bing Wang
Yanjun Liu
Tianqi Lu
July 1, 2026
Clinical Scorecard: Epstein-Barr Virus-Related Gastric Carcinoma Developing One Year Post-Metabolic Bariatric Surgery: A Case Study and Review of Existing Literature
At a Glance
Category Detail
Condition Epstein-Barr Virus-Associated Gastric Carcinoma (EBVaGC) Key Mechanisms EBV infection leading to gastric adenocarcinoma, with specific molecular characteristics including EBER positivity and ARID1A mutation. Target Population Patients undergoing metabolic bariatric surgery, particularly those with persistent gastrointestinal symptoms. Care Setting Postoperative evaluation following metabolic bariatric surgery.
Key Highlights
First documented case of EBVaGC post-bariatric surgery. Patient developed gastric adenocarcinoma one year after single anastomosis sleeve ileal bypass. Biopsy revealed negative Helicobacter pylori status. Postoperative chemotherapy with oral S-1 was administered. Routine gastroscopic assessment recommended at approximately 1 year post-surgery. Guideline-Based Recommendations
Diagnosis
Incorporate EBER-ISH for suspicious gastric lesions. Lower threshold for diagnostic endoscopy in patients with unexplained nutritional abnormalities. Management
Consider routine gastroscopy at 1 year post-MBS to evaluate gastric mucosal health. Monitoring & Follow-up
Postoperative molecular and minimal residual disease assessments are recommended. Risks
Potential for EBVaGC despite negative plasma EBV results. Patient & Prescribing Data
62-year-old male with a history of obesity and type 2 diabetes.
Postoperative oral S-1 chemotherapy regimen planned for 8 cycles.
Clinical Best Practices
Monitor metabolic parameters post-bariatric surgery. Perform routine endoscopic evaluations for early detection of gastric lesions. Related Resources & Content
